appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Dr. Lal PathLabs Ltd
LALPATHLAB
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Dr Lal Pathlabs Private Limited is headquartered in Gurgaon, Haryana, India and is a medical laboratory operator.
Brands
Investor PresentationView older
View Older PresentationsBrands
PeersCompare with peers
Apollo Hospitals Enterprise Ltd
Max Healthcare Institute Ltd
Fortis Healthcare Ltd
Global Health Ltd
Narayana Hrudayalaya Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Increased Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has increased by 2.50%
Recent NewsAll news
Technical Breakout Stocks: Alembic Pharma, Dr Lal PathLabs and Zydus Wellness hit 52-week highs; what should traders do? - Market Roundup
4 days ago•Economic Times
Healthcare at new high; Lupin, Glenmark among 5 stocks for up to 15% upside
3 weeks ago•Business Standard
Recent EventsAll events
Shareholders meeting
Dr. Lal Path Labs Ltd. has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on Jun 29, 2024. Further, the company has informed the Exchange regarding voting results. | Download
Dr. Lal Path Labs Ltd. has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on Jun 29, 2024. Further, the company has informed the Exchange regarding voting results. | Download
Cash Dividend
Final • Div/Share: ₹ 6
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant